GeoVax Labs (GOVX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic focus and innovation

• Emphasizes innovation, differentiation, acceleration, and collaboration, supported by a strong IP portfolio and targeting underserved populations.

• Pursues expedited registration pathways and global distribution through business development and collaborations.

• Positions itself as a compelling investment opportunity in biotechnology, balancing growth potential with risk.

Pipeline highlights and clinical progress

• GEO-CM04S1, a next-generation COVID-19 vaccine, received nearly $400 million in BARDA funding for a phase IIb trial.

• Vaccine platform uses MVA technology, offering safety, stability, and dual antigen (spike and nucleocapsid) approach for broader and longer-lasting immunity.

• Clinical data shows protection against multiple COVID-19 variants and durability of 8–12 months, with a large head-to-head trial launching next year.

• Three ongoing trials, including studies in immunocompromised patients and as a booster, with key data milestones expected by year-end.

Mpox vaccine and global health response

• WHO declared a global health emergency for mpox, with severe vaccine shortages, especially in Africa.

• Has produced a cGMP master seed virus for mpox vaccine, positioning as the closest alternative supplier globally.

• Engaged in regulatory and emergency use discussions to expedite mpox vaccine supply.